From Mutation Discovery to Cellular Biology

From mutation discovery to cellular biology: How cells interpret mutations in hematologic malignancies

Over the past two decades, research in pre-cancer and hematologic malignancies has moved from discovering mutations to building mutation-informed risk models. The next question is how individual cells interpret those mutations to drive disease.

In this World Single-Cell Day 2026 talk, Terra L. Lasho, PhD, of Mayo Clinic shares single-cell multiomics data from the Tapestri® platform on TET2 and IDH, two mutations that converge on a shared epigenetic axis. You’ll learn:

• How single-cell DNA + protein analysis reveals distinct clonal architectures in AITL across lymph node and spleen
• When IDH2 is acquired relative to founder TET2 and DNMT3A mutations
• Why TET2/IDH co-mutant clones in CMML extend beyond the myeloid compartment, including into NK cells
• Why responses to IDH inhibition may reflect changes in cell state rather than clearance of the clone
• How triomics connects genotype, phenotype, and gene expression in the same cell